

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/5/2011; page 1

Suggested Formula Chloroquine Phosphate 161 mg Oral Capsules (Powder blend, 10 x Size #3 Capsules)	FIN	F 002 310v2
--	-----	-------------

Note: Chloroquine Phosphate 161 mg is equivalent to Chloroquine 100 mg.

# **SUGGESTED FORMULATION**

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Chloroquine Phosphate (Diphosphate),USP	1.610	g				
Lactose (Monohydrate), NF	TBD					
Sodium Chloride, USP	As required					

# **SPECIAL PREPARATORY CONSIDERATIONS**

<u>Ingredient-Specific Information</u>	
Light sensitive (protect from lig	ght whenever possible): Chloroquine Phosphate
Suggested Preparatory Guidelines	
Non-Sterile Preparat	ion Sterile Preparation
Processing Error / Testing Considerations:	To account for processing errors and considerations during preparation, it is suggested to measure an additional 20 to 25% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/5/2011; page 2

Suggested Formula

Chloroquine Phosphate 161 mg Oral Capsules (Powder blend, 10 x Size #3 Capsules)

FIN

F 002 310v2

# **SUGGESTED PREPARATION (for 10 Size #3 Capsules)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Chloroquine Phosphate (Diphosphate), USP §	1.610	g			
Lactose (Monohydrate), NF	TBD				
Sodium Chloride, USP	As required		<b>⊗</b>		

- \* Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

	Preparatory Instruction
1.	Lactose (Monohydrate) requirements for 10 x size #3 capsules
	A. Calculate the amount of Lactose (Monohydrate) required for the batch. Refer to attached appendix for details.
2.	Powder preparation:
	A. Triturate the Chloroquine Phosphate to form a fine, homogeneous powder.
	B. By geometric addition, combine and mix the following ingredients together:
	-Fine, homogeneous powder (Step 2A) -Lactose (Monohydrate) (Quantity determined in appendix (I))
3.	Product transfer:
	Fill each of 10 Size #3 capsules with the powder blend (Step 2B). Close each capsule tightly.
	Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.
4.	Validation technique (average capsule weight):
	The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix $(G) + 0.161$ g together.
5.	Product transfer:

Transfer the final product into the specified dispensing container (see "Packaging Requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/5/2011; page 3

Suggested Formula	Chloroquine Phosphate 161 mg Oral Capsules (Powder blend, 10 x Size #3 Capsules)	FIN	F 002 310v2
----------------------	--	-----	-------------

## SUGGESTED PRESENTATION

Estimated Beyond-Use Date		6 months, as per USP.	Packaging Requirements		Tightly closed, light-resistant vials.	
	1	Use as directed. Do not exceed dose.	d prescribed	6	Keep in a dry place.	
	2	Keep out of reach of children.		7	Cap tightly after use.	
A	3	Protect from light.		8	Keep at room temperature (20°C – 23°C).	
Auxiliary Labels	5	Consult your health care pra any other prescription or counter medications are curr used or are prescribed for futu May impair mental and/or phys Use care when operating	over-the- ently being are use. sical ability.	9	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	
		machinery.				
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.					
Patient Instructions	If allergic reactions occur, consult your pharmacist.					

## **REFERENCES**

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 91.
2.	Lactose. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2003: 323.
3.	Chloroquine (Monograph). In: O'Neil MJ. <i>The Merck Index 13<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 373.
4.	USP <795>. <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2457.
5.	Chloroquine Phosphate (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 444.
6.	Chloroquine Phosphate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 2 <sup>nd</sup> Edition. American Pharmaceutical Association; 2000: 79.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/5/2011; page 1

A									
	Procedure								
1.	. Capsule filling:								
	a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight. Also, triturate the ingredient powder first if required in formulation								
	Pl	ug each amount into Step 2, column E	3.	(8)					
2.	Volur	ne Percent Occupied:							
			Column A	Column B		umn C			
	<u>I</u>	ngredients	Quantity Required per capsule	Average capsule fill weight	A/B x 1 percent	00 equals filled			
	a. Cł	aloroquine Phosphate	0.161 g	g		%			
	b. La	ctose (Monohydrate)		g					
	c. To	otal (add column C together)	E			% ( <b>D</b> )			
3.	Calcu	late the quantity of Lactose (Monol	hydrate) required for the	batch:					
	a. Pe	rcent of Lactose (Monohydrate) requi	ired = 100% - (D)			% ( <b>E</b> )			
	b. Av	verage capsule fill weight of Lactose (	Monohydrate) (from colu	mn B, Step 2b):		g ( <b>F</b> )			
	c. Qu	nantity of Lactose (Monohydrate) requ	uired per capsule = $[(E) \div (E)]$	$100 \times (F)$ ]		g ( <b>G</b> )			
	d. To	otal quantity of Lactose (Monohydrate	e) required for the batch =	10 capsules $\times$ (G)		g ( <b>H</b> )			
	e. To		g ( <b>I</b> )						

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.